Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials

  • H. Imran
  • I. M. Tleyjeh
  • C. A. S. Arndt
  • L. M. Baddour
  • P. J. Erwin
  • C. Tsigrelis
  • N. Kabbara
  • V. M. Montori


A recent meta-analysis, which included non-placebo open-labeled trials, showed that fluoroquinolone prophylaxis reduces mortality in neutropenic patients, whereas two recent large trials failed to show a similar benefit. Therefore, we performed a meta-analysis of randomized, blinded, placebo-controlled trials of fluoroquinolone prophylaxis in neutropenic patients. We searched several databases for relevant trials in any language. We used random effects models for pooling dichotomous data and assessed the between-study inconsistency with I 2. Two investigators independently assessed the eligibility and quality of the included trials. A total of 2,721 patients were randomized in eight eligible trials. Compared to the placebo, there was a statistically non-significant but consistent decrease in mortality with fluoroquinolone prophylaxis (4.5% vs. 3.9%, relative risk (RR) 0.76, 95% confidence interval (CI) 0.54, 1.08, p = 0.13, I 2 = 0%). Significant inconsistency, however, accompanied the pooled analysis of febrile episode (39% vs. 31%, RR 0.76, 95% CI 0.55, 1.03, p = 0.08, I 2 = 96.5%). To an extent, this inconsistency was explained in the subgroup analyses by the type of patient population studied and the type of fluoroquinolone used (p for interaction ≤0.01 for both). The RR of febrile episodes for two trials of outpatients with solid tumors, including lymphomas, was RR 0.34 (95% CI 0.14, 0.80) and 0.60 (95% CI 0.33, 1.10) for two trials using levofloxacin prophylaxis. The RR in one of the two trials that used levofloxacin significantly favored the intervention, 0.76 (95% CI 0.70, 0.83). Fluoroquinolone prophylaxis reduces the risk of febrile episodes in neutropenic outpatients with solid tumors, including lymphomas, and is associated with a statistically non-significant, yet clinically important, decrease in mortality in all neutropenic patients. Prophylaxis with levofloxacin may reduce febrile episodes in neutropenic hematology patients and stem cell transplant recipients.



We would like to extend our special thanks to Dr. Michael Cullen, Cancer Centre, University Hospital Birmingham, Birmingham, UK, for providing us with the mortality data [16] and reviewing the paper.

Conflict of interest statement

None for all authors.


  1. 1.
    Bodey GP, Buckley M, Sathe YS, Freireich EJ (1996) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340Google Scholar
  2. 2.
    Dale DC, Guerry DT, Wewerka JR, Bull JM, Chusid MJ (1979) Chronic neutropenia. Medicine (Baltimore) 58:128–144Google Scholar
  3. 3.
    Lucas KG, Brown AE, Armstrong D, Chapman D, Heller G (1996) The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 77:791–798PubMedCrossRefGoogle Scholar
  4. 4.
    Schimpff SC (1986) Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 80:13–20PubMedGoogle Scholar
  5. 5.
    Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foà R, Del Favero A (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977–987PubMedCrossRefGoogle Scholar
  6. 6.
    Kamana M, Escalante C, Mullen CA, Frisbee-Hume S, Rolston KVI (2005) Bacterial infections in low-risk, febrile neutropenic patients: over a decade of experience at a comprehensive cancer center. Cancer 104:422–426PubMedCrossRefGoogle Scholar
  7. 7.
    Meijer E, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK, Verdonck LF (2004) Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transpl Infect Dis 6:171–178PubMedCrossRefGoogle Scholar
  8. 8.
    Fernández-Mosteirin N, Salvador-Osuna C, Gimeno Lozano JJ, Marco Lamata ML, Blasco Alberdi M, Rubio Felix D, Giralt Raichs M (2005) Incidence of febrile episodes in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation (in Spanish). An Med Interna 22:213–216PubMedGoogle Scholar
  9. 9.
    Lyman GH, Delgado DJ (2003) Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 98:2402–2409PubMedCrossRefGoogle Scholar
  10. 10.
    Sigurdardottir K, Digranes A, Harthug S, Nesthus I, Tangen J-M, Dybdahl B, Meyer P, Hopen G, Løkeland T, Grøttum K, Vie W, Langeland N (2005) A multi-centre prospective study of febrile neutropenia in Norway: microbiological findings and antimicrobial susceptibility. Scand J Infect Dis 37:455–464PubMedCrossRefGoogle Scholar
  11. 11.
    Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, Reuter S, von Baum H, Marre R (2005) Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 24:111–118PubMedCrossRefGoogle Scholar
  12. 12.
    Carratalá J, Fernández-Sevilla A, Tubau F, Callis M, Gudiol F (1995) Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 20:557–560; discussion 561–563PubMedGoogle Scholar
  13. 13.
    Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KVI, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751PubMedCrossRefGoogle Scholar
  14. 14.
    Gafter-Gvili A, Fraser A, Paul M, Leibovici L (2005) Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979–995PubMedGoogle Scholar
  15. 15.
    Jüni P, Altman DG, Egger M (2001) Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323:42–46PubMedCrossRefGoogle Scholar
  16. 16.
    Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353:988–998PubMedCrossRefGoogle Scholar
  17. 17.
    Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, Kern WV (2006) Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 107:1743–1751PubMedCrossRefGoogle Scholar
  18. 18.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRefGoogle Scholar
  19. 19.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560PubMedCrossRefGoogle Scholar
  20. 20.
    Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326:219PubMedCrossRefGoogle Scholar
  21. 21.
    Fu KP, Lafredo SC, Foleno B, Isaacson DM, Barrett JF, Tobia AJ, Rosenthale ME (1992) In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother 36:860–866PubMedGoogle Scholar
  22. 22.
    Karp JE, Merz WG, Hendricksen C, Laughon B, Redden T, Bamberger BJ, Bartlett JG, Saral R, Burke PJ (1987) Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 106:1–7PubMedGoogle Scholar
  23. 23.
    Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Takvorian T, Mayer R, Kalish L, Finberg R (1991) Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 51:630–636PubMedCrossRefGoogle Scholar
  24. 24.
    Rafecas FJ et al (1989) Oral ciprofloxacin in the prophylaxis of bacterial infection in neutropenic patients. A randomized, double blind, comparative clinical study. Revista Espanola de Quimioterapia 2:174–177Google Scholar
  25. 25.
    Schroeder M, Schadeck-Gressel C, Selbach J, Westerhausen M (1992) Antibiotic prophylaxis with gyrase inhibitors during cytostatically induced granulocytopenias in patients with solid tumors: a double-blind prospective randomized study. Onkologie 15:476–479CrossRefGoogle Scholar
  26. 26.
    Talbot GH, Cassileth PA, Paradiso L, Correa-Coronas R, Bond L (1993) Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group. Antimicrob Agents Chemother 37:474–482PubMedGoogle Scholar
  27. 27.
    Thomas X, Troncy J, Belhabri A, Thiebaut A, Bouheddou N, Michallet M, Fleurette J, Pivot C, Fiere D, Archimbaud E (2000) Effectiveness of combined vancomycin and pefloxacine in gastrointestinal decontamination for preventing infections after chemotherapy-induced bone marrow aplasia. A randomized double-blind study (in French). Presse Med 29:1745–1751PubMedGoogle Scholar
  28. 28.
    Rolston KVI (1998) Risk assessment and risk-based therapy in febrile neutropenic patients. Eur J Clin Microbiol Infect Dis 17:461–463PubMedGoogle Scholar
  29. 29.
    Somolinos N, Arranz R, Del Rey MC, Jimenez ML (1992) Superinfections by Escherichia coli resistant to fluoroquinolones in immunocompromised patients. J Antimicrob Chemother 30:730–731PubMedCrossRefGoogle Scholar
  30. 30.
    Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R (1994) Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38:681–687PubMedGoogle Scholar
  31. 31.
    Gafter-Gvili A, Paul M, Fraser A, Leibovici L (2007) Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 59:5–22PubMedCrossRefGoogle Scholar
  32. 32.
    Tascini C, Menichetti F, Bozza S, Fedele M, Preziosi R, Allegrucci M, Del Favero A, Micozzi A, Martino P, Bistoni F (1999) Molecular typing of fluoroquinolone-resistant and fluoroquinolone-susceptible Escherichia coli isolated from blood of neutropenic cancer patients in a single center. Clin Microbiol Infect 5:457–461PubMedGoogle Scholar
  33. 33.
    Martino R, Subira M, Altes A, López R, Sureda A, Domingo-Albós A, Pericas R, Brunet S (1998) Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity. Acta Haematol 99:206–211PubMedCrossRefGoogle Scholar
  34. 34.
    Reuter S, Kern WV, Sigge A, Döhner H, Marre R, Kern P, von Baum H (2005) Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 40:1087–1093PubMedCrossRefGoogle Scholar
  35. 35.
    Tjan-Heijnen VCG, Postmus PE, Ardizzoni A, Manegold CH, Burghouts J, van Meerbeeck J, Gans S, Mollers M, Buchholz E, Biesma B, Legrand C, Debruyne C, Giaccone G (2001) Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 12:1359–1368PubMedCrossRefGoogle Scholar
  36. 36.
    Cruciani M, Malena M, Bosco O, Nardi S, Serpelloni G, Mengoli C (2003) Reappraisal with meta-analysis of the addition of gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 21:4127–4137PubMedCrossRefGoogle Scholar
  37. 37.
    Tang JL, Liu JL (2000) Misleading funnel plot for detection of bias in meta-analysis. J Clin Epidemiol 53:477–484PubMedCrossRefGoogle Scholar
  38. 38.
    Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I (2006) The case of the misleading funnel plot. BMJ 333:597–600PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • H. Imran
    • 1
  • I. M. Tleyjeh
    • 2
  • C. A. S. Arndt
    • 3
  • L. M. Baddour
    • 4
  • P. J. Erwin
    • 5
  • C. Tsigrelis
    • 4
  • N. Kabbara
    • 6
  • V. M. Montori
    • 7
  1. 1.Division of Pediatric Hematology/OncologyUniversity of South AlabamaMobileUSA
  2. 2.Division of Infectious Diseases, Department of MedicineKing Fahd Medical CityRiyadhSaudi Arabia
  3. 3.Division of Pediatric Hematology/OncologyMayo Clinic College of MedicineRochesterUSA
  4. 4.Division of Infectious DiseasesMayo Clinic College of MedicineRochesterUSA
  5. 5.Mayo Medical LibrariesMayo Clinic College of MedicineRochesterUSA
  6. 6.Hematopoietic Stem Cell Transplantation Unit, Hematology DepartmentHôpital Saint LouisParisFrance
  7. 7.Knowledge and Encounter Research UnitMayo Clinic College of MedicineRochesterUSA

Personalised recommendations